MiR-181a: a potential biomarker of acute muscle wasting following elective high-risk cardiothoracic surgery

Susannah AA Bloch¹,²*, Anna VJ Donaldson², Amy Lewis¹, Winston AS Banya², Michael I Polkey²†, Mark JD Griffiths²,³† and Paul R Kemp¹†

Abstract

Introduction: Acute muscle wasting in the critically ill is common and associated with significant morbidity and mortality. Although some aetiological factors are recognised and muscle wasting can be detected early with ultrasound, it is not possible currently to predict in advance of muscle loss those who will develop muscle wasting. The ability to stratify the risk of muscle wasting associated with critical illness prior to it becoming clinically apparent would provide the opportunity to predict prognosis more accurately and to intervene at an early stage. MicroRNAs are small non-coding RNAs that modulate post-transcriptional regulation of translation, some are tissue specific and can be detected and quantified in plasma. We hypothesised that certain plasma microRNAs could be biomarkers of ICU acquired muscle weakness.

Methods: Plasma levels of selected microRNAs were measured in pre- and post-operative samples from a previously reported prospective observational study of 42 patients undergoing elective high-risk cardiothoracic surgery, 55% of whom developed muscle wasting.

Results: The rise in miR-181a was significantly higher on the second post-operative day in those who developed muscle wasting at 1 week compared to those who did not (p = 0.03). A rise in miR-181a of greater than 1.7 times baseline had 91% specificity and 56% sensitivity for subsequent muscle wasting. Other microRNAs did not show significant differences between the groups.

Conclusion: Plasma miR-181a deserves further investigation as a potential biomarker of muscle wasting. Additionally, since mir-181a is involved in both regulation of inflammation and muscle regeneration and differentiation; our observation therefore also suggests directions for future research.
especially if changes preceded loss of muscle cross-sectional area. Lastly a predictive biomarker of acute muscle wasting would facilitate selection of high-risk patients and thus, allow enrichment of stratified medicine trials.

MicroRNAs are small non-coding RNAs that modify translation. Many are tissue-specific and can be quantified reliably and reproducibly in blood [8-10]. The role of microRNAs in the pathogenesis of disease is a fast expanding area of research. However, their potential use as biomarkers is also increasingly recognised, as they circulate in blood, are often tissue-specific and are resistant to breakdown as they are believed to circulate in protective exosomes [10,11], for example, as prognostic and diagnostic markers in acute coronary syndromes [9] and in diagnosis of solid and haematological cancers [11].

Our group has previously shown that blood microRNA profile reflects muscle phenotype and muscle atrophy in chronic obstructive pulmonary disease (COPD) [12,13]. Therefore, we hypothesised that muscle-specific microRNAs, which are known to be involved in muscle homeostasis and metabolism (1,133,206,499 [14]) and have been found to be associated with muscle wasting by our group [12,13], as well as those involved in the regulation of muscle regeneration and inflammation (30b, 181a - believed to be the major member of the 181 family functional in muscle [14,15]) might prove to be useful biomarkers of early development of acute muscle wasting in the critically ill patient. Last, the role for these microRNAs in particular as a biomarker was suggested by our recent observation that muscle expression of these microRNAs is reduced in patients with established ICU-acquired muscle wasting [16].

**Material and methods**

**Patient recruitment and study design**

Blood from a previously reported prospective observational study was used [17]. Briefly patients undergoing a high-risk elective procedure requiring post-operative admission to adult critical care were recruited. Patients involved in the study gave informed written consent to take part. The study was ethically approved by the local research ethics committee approval under the National Institute for Health Research (NIHR) Respiratory Biomedical Research Unit (BRU) at the Royal Brompton and Harefield National Health Service (NHS) trust (10/H0504/9). High-risk patients were defined by the surgical team and EuroSCORE assessment [18]. Malignancy, pre-existing muscle or neuromuscular disease, or contraindication to serial blood sampling excluded patients from the study. Measurement of the cross-sectional area of the right rectus femoris muscle by ultrasound (US RF<sub>csa</sub>) (see below) was used to assess quadriceps muscle mass pre-operatively, on the day before surgery. This was repeated at day 7 of admission or on discharge from hospital if earlier than day 7. Bloods were taken pre-operatively for analysis (baseline), on the 1st (D1) and 2nd (D2) post-operative days and at day 7 or at discharge from hospital if earlier (D7). D7 and discharge earlier than day 7 were considered and analysed as the same time point: this only applied to three patients in the non muscle-wasting group and one in the muscle-wasting group. Following centrifuge separation of plasma (1,500 g for 10 minutes) samples were aliquoted and stored at −80°C within 2 hours of collection.

**Definition of quadriceps wasting by measurement of cross-sectional area of the rectus femoris by ultrasound**

B-mode ultrasound (US) imaging with a 10-MHz 12 L-RS probe was used (Logiq E, GE Healthcare, Buckinghamshire, UK) to measure the US RF<sub>csa</sub> as previously described [17,19,20]. Three separate images were obtained and the RF<sub>csa</sub> estimated using Image-J software (National Institutes of Health, USA). Either the point 2/3 or 4/5 of the distance from the anterior superior iliac spine to the superior border of the patella (both points have been validated by our group) was used to measure the US RF<sub>csa</sub> and the same point measured for repeated measures. The mean of these three measurements was used. Images were excluded (n = 3) if the edges of the RF muscle could not be defined well enough to calculate the RF<sub>csa</sub> for example if the patient was very oedematous. Patients were classified as those who developed muscle wasting if they developed more than 9.24% muscle wasting, as determined by the previously calculated coefficient of variation, based on the reproducibility of the measure in preliminary studies [17].

**Plasma microRNA extraction and quantification**

In order to provide normalisation for the RNA extraction process we spiked in an exogenous control (Caenorhabditis elegans microRNA, C-39). Quantification of microRNAs in plasma and normalisation to a spiked in control has been previously described [21]. RNA was extracted with TRIzol™ Reagent (Invitrogen) and miRNAeasy RNA and small RNA extraction kits (Qiagen). MicroRNAs were quantified using NCODE™ VILO™ miRNA cDNA synthesis and sybr-green qPCR kits (Invitrogen). Full details of these methods, including primers used, have been previously published by our group [12]. Samples were excluded if the PCR melt curves suggested multiple products or duplicates were inconsistent. Excluded samples were equally distributed between both groups (non muscle-wasting group 48/380 and in the muscle-wasting group 57/460, P = 0.91, chi-squared test).

**Data and statistical analysis**

MicroRNA data were non-parametrically distributed; as such the data are presented as median with IQR. Repeated
measures Friedman's test with Dunn's correction for multiple comparisons (all time points to the pre-operative baseline) was used for within-group analysis. The Kolmogorov-Smirnov (KS) test was used for the between-group analysis of miR-181a fold-change, as the variance was different between the groups. Statistical analysis and figure construction was carried out using Graphpad PRISM 6 (GraphPad Software, San Diego, CA, USA). Receiver operating characteristic (ROC) curve analysis and calculation of specificity and sensitivity were carried out using Graphpad PRISM 6. Positive predictive value and negative predictive value were calculated using www.medcalc.org.

**Results**

**Patients**
The demographic data and clinical characteristics of this patient cohort have been previously published [17]. Of the 42 patients included in the data analysis 55% (n = 23) developed muscle wasting. Those who developed muscle wasting and those who did not were well-matched in terms of age, sex, body mass index, co-morbidities and surgical risk (EuroSCORE) at baseline (Table 1), indicating that these factors cannot be used to predict skeletal muscle loss. Clinical data for the two groups of patients are shown in Table 1; the median length of ICU stay was 1 day for non muscle-wasting patients and 2 days for those with muscle wasting (P = 0.62, Mann-Whitney test). Further clinical data including indication for cardiac surgery can be found in the original study and its online supplement [17].

**MicroRNAs**
miR-133 and -206 were not detectable. miR-16 was quantified as a control microRNA [21]. No statistical difference between muscle-wasting and non muscle-wasting patients was found in plasma concentration of these microRNAs at baseline, or in the absolute values at any other time point. Repeated measurements were therefore expressed and analysed relative to the patient's own baseline (fold-change). miR-30b and -499 remained unchanged both between and within groups over time (Figure 1).

**Table 1 Demographic data, co-morbidities and critical care data for non muscle-wasting (n = 19) and muscle-wasting patients (n = 23)**

|                          | Non muscle-wasting patients (n = 19) | Muscle-wasting patients (n = 23) | P-value (t-test, Mann-Whitney*, chi-squared*) |
|--------------------------|--------------------------------------|---------------------------------|---------------------------------------------|
| **Demographic data**     |                                      |                                 |                                             |
| Age, years               | 65.7 ± 17.2                          | 62.0 ± 16.2                     | 0.47                                        |
| Sex, male/female         | 9/10                                 | 12/11                           | 0.76*                                       |
| Body mass index, kg/m2   | 26.6 ± 4.6                           | 24.7 ± 4.1                      | 0.18                                        |
| EuroSCORE                | 5.3 ± 1.8                            | 5.5 ± 2.6                       | 0.76                                        |
| Pre-operative creatinine, umol/L | 81.3 ± 23.6                         | 77.3 ± 17.1                     | 0.52                                        |
| Pre-operative creatinine clearance, ml/minute | 84.7 ± 36.1                         | 86.8 ± 34.7                     | 0.66                                        |
| **Pre-operative co-morbidities, n** |                                    |                                 |                                             |
| Ischaemic heart disease  | 10                                   | 8                               | 0.24*                                       |
| Structural heart disease | 9                                    | 11                              | 0.97*                                       |
| Dysrhythmia              | 2                                    | 3                               | 0.80*                                       |
| Systemic hypertension    | 7                                    | 5                               | 0.94*                                       |
| Pulmonary hypertension   | 1                                    | 2                               | 0.66*                                       |
| Hypercholesterolaemia    | 7                                    | 10                              | 0.66*                                       |
| Congenital cardiac disease | 3                                  | 6                               | 0.42*                                       |
| Diabetes                 | 3                                    | 1                               | 0.21*                                       |
| Obstructive lung disease | 3                                    | 2                               | 0.45*                                       |
| **Outcome data**         |                                      |                                 |                                             |
| C-reactive protein day 2 | 165 ± 60                             | 189 ± 68                        | 0.23                                        |
| ICU length of stay, median (IQR) | 1 (1 to 2.5)                        | 2 (1 to 3)                      | 0.62*                                       |
| Hospital length of stay, median (IQR) | 8 (7 to 11)                        | 9 (8 to 10.5)                   | 0.44*                                       |

Data presented as mean ± SD unless otherwise stated. *Weight unavailable for two patients in the muscle-wasting group, therefore, n = 21. Data adapted from previously published study [17]. p values calculated by t-test, # - Man-Whitney or * - Chi-squared as appropriate.
miR-181a
Median fold-change in plasma miR-181a at D2 was 2.15 (IQR 0.40 to 3.15) in those who developed muscle wasting compared to 1.02 (IQR 0.50 to 1.60) in those who did not ($P=0.03$) (Figure 1). ROC curve analysis for the increase in D2 miR-181a gave an area under the curve of 0.6. A rise in miR-181a at D2 greater than 1.7 times baseline gave a specificity of 91% and sensitivity of 56% for acute muscle wasting. This cut off resulted in a positive predictive value of 91% and a negative predictive value of 56%.

miR-1
miR-1 was significantly elevated at D1 compared to baseline in both groups (median 4.03 times higher (IQR 1.65 to 7.84) in patients with muscle wasting and 5.14 (IQR 1.31 to 14.00 in patients with no muscle wasting); $P<0.01$ for both). The fold-change increase in plasma miR-1 was not different between the two groups. miR-1 returned to baseline by D2 in both groups (Figure 1).

miR-16
miR-16 was significantly reduced at D1 compared to baseline in both groups (median 0.71 of baseline (IQR 0.21 to 0.92) in patients with muscle wasting, $P<0.01$, and median 0.41 of baseline (IQR 0.31 to 0.87) in patients with no muscle wasting, $P<0.05$). The fold-change reduction was not different between the groups and returned to baseline in both (Figure 1).
Discussion
We provide preliminary data that show that following elective high-risk cardiothoracic surgery, both patients with and without subsequent muscle wasting exhibited changes in the circulating microRNA profile. Despite the low area under the ROC curve (0.6), we found that a 1.7-fold increase in miR-181a was 91% specific for a subsequent reduction in RF_{CSA}, however, its value in excluding a subsequent reduction in RF_{CSA} was less striking. These data are preliminary and as with all biomarker studies should be repeated in a validation cohort, and with more frequent time point measures to define the window after surgery (or admission) with the greatest clinical utility.

Critique of the method
This is a relatively small study with a limited population of patients. In evaluating new tests it is important to avoid scenarios where there is a high pre-test probability of the condition one is testing for (in this case quadriceps loss assessed by RF_{CSA}) to provide a fair evaluation of the test. Our disease model included patients with brief ICU stays and an uncomplicated post-operative course. Nevertheless, we achieved an approximately 50:50 split between those who developed a reduction in RF_{CSA} at the seventh post-operative day and those who did not, suggesting that the model is suitable for evaluating the test. While this model of acute muscle wasting following cardiothoracic surgery allowed us to control for many of the other factors that occur in the critically ill, and thus, investigate a disease marker that is specific to muscle wasting, it remains to be seen whether our results are generalisable to a wider ICU population (including both a greater sample size and wider variation in ICU disease). It may be that these changes are only seen in this limited cohort of patients. It is also important to note that the muscle wasting described here was mild, no patients developed debilitating muscle weakness and none reached the diagnostic criteria for true ICU-acquired weakness as set out by Stevens et al. [22]. A measure of muscle strength and the relationship between this and muscle wasting and changes in microRNAs would potentially add to the study, however, we found that the Medical Research Council (MRC) strength score was not discriminatory enough (all but four patients scoring 60/60 at 1 week) and handheld dynamometry was limited by the pain of sternal wounds following surgery; thus, a more detailed strength evaluation would require use of a non-volitional technique such as magnetic nerve stimulation [23]. It is possible that in a sicker group of patients a more detailed strength evaluation would be required in drawing mechanistic conclusions. MicroRNAs circulate in the blood in exosomes or bound to protein and high-density lipoproteins. The regulation, specificity and secretion of microRNA into the circulation is not fully understood [9]. In COPD, specific microRNAs change in opposite directions in muscle and plasma, for example, miR-1 was reduced in the muscle of patients with COPD and reflected muscle wasting, whereas it was increased in the plasma of the same patients [12,13], consistent with our observation that miR181a was reduced in the muscle of patients with established ICU-acquired weakness [16]. It is also important to note that as the field of microRNA research increases there may be other, as yet unknown, microRNA that would be better biomarkers than the ones targeted in this work. Furthermore, there is significant variability between individuals and the standard errors are large. The reasons for this are unclear; however, these variations are in line with those seen in the literature, where similar fold-change differences in relatively small numbers of participants are also described [10]. Also, it may be that as our understanding of microRNA regulation in the circulation improves, normalisation of
the rise in miR-181a seen here suggests potential directions for future research especially given its established roles in inflammation and muscle metabolism [15,26].

Clinical perspective
Our data suggest that a rise in miR-181a early in ICU admission may have a high specificity for muscle wasting at 1 week. The high positive predictive value of this test (91%) allows it to be used to identify at-risk patients. However, due to the relatively low sensitivity (56%) not all patients at risk of muscle wasting will be identified, therefore this test could not be used to exclude a diagnosis of acute muscle wasting. Several possible reasons suggest themselves for the poorer sensitivity than specificity of this marker. First, mir-181a may indeed have a mechanistic role; as it is acknowledged that ICU-acquired weakness is multi-factorial then if mir-181a were mechanistic, it would only capture cases in which this mechanism was the major underlying factor. Second, while muscle wasting is long-lasting, both in the ICU and in other clinical scenarios, the miR-181a rise was not. Thus, it is conceptually possible that patients who had weakness at D7 but only a small fold-change in miR-181a at D2 would have had a greater rise had it been measured, for example, at D4. Last, as circulating, microRNA levels depend on export of the microRNA from cells, other factors increasing cell permeability to this miRNA could contribute to the presence of miR-181a in the plasma.

Currently there is no effective therapy for muscle atrophy beyond ensuring adequate nutrition and facilitating early exercise and mobilisation. However, there is increasing interest in preventing muscle loss by the application of external neuromuscular electrical stimulation. Similarly new generation anabolic agents are presently being evaluated in animals, for example, those targeting the myostatin signalling pathway [27,28]. In developing translational studies, which bring novel medicines to patients, it will be useful to stratify patients by the likelihood of developing subsequent muscle loss and circulating miR-181a could be useful for this purpose by reducing the size of a proof-of-concept study.

The biological role of miR-181a is not fully understood. It is expressed in many different tissues and is not muscle specific. However, miR-181a is essential for regeneration and differentiation in muscle after tissue injury [15]. miR-181a is expressed highly in differentiating and regenerating muscle, and by suppression of Homeobox Protein A11 (HOX-A11) it promotes muscle differentiation [15]. Furthermore, in other tissues it has been shown to be involved in the regulation of inflammatory pathways [26,29]. Both of these pathways may be relevant in the response of muscle to critical illness [30]. However, miR-181b has been found to be reduced in blood obtained from ICU patients with sepsis [31]. Sepsis is certainly a major aetiological factor in the development of critical illness-related acute muscle wasting [30] but our patients were not septic. Furthermore, although miR-181a and miR-181b are from the same family of microRNAs, and likely to be co-transcribed, potential differences in their function are not fully understood [15]. miR-181a is the major member of the miR-181 family that has been shown to be functional in human muscle [15].

Conclusion
In conclusion we have evaluated the potential role of selected microRNAs for the prediction of subsequent muscle loss in patients undergoing elective high-risk cardiothoracic surgery. We found that an elevation of miR-181a may represent a specific marker of quadriceps wasting, which deserves further prospective evaluation in larger unselected populations of critically ill patients.

Key messages
- Acute muscle wasting in the critically ill is difficult to accurately predict and as such the search for a biomarker of acute muscle wasting in these patients is important.
- We identify miR-181a as a potential specific biomarker of acute muscle wasting in the critically ill that deserves further prospective evaluation.

Endnote
^Of note, in this case the positive predictive value and specificity, and the negative predictive value and sensitivity are the same numerically because the number of true positives and true negatives are numerically the same.

Abbreviations
COPD: chronic obstructive pulmonary disease; KS: Kolmogorov-Smirnov; ET: et al. Critical Care; ROC: receiver operating characteristic; US: ultrasound; C15: cross-sectional area of the rectus femoris muscle.

Competing interests
The authors declare that they have no competing interest.

Authors’ contributions
SB carried out the clinical study, sample processing and data analysis and was responsible for the manuscript draft and revisions. AD participated in the method development of microRNA extraction from plasma, helped with sample processing and manuscript revision. AL also participated in the method development of microRNA extraction from plasma, helped with sample processing and manuscript revision. WB provided statistics input, approved the statistical methods and revised the statistical section of the manuscript. MG supervised and designed the clinical aspects of the project and guided the project with equal input both practically and in writing this manuscript as the other senior authors, MIP and PK. PK supervised and was...
involved in the design of the molecular aspects of the project and guided the project with equal input both practically and in writing this manuscript as the other senior authors, MG and MIP. MIP was involved in the study design and conceiving the methods, and supervised both the clinical work and analysis of the results. All authors read and approved the final manuscript.

**Authors’ information**

Michael I Polkey, Mark JD Griffiths and Paul R Kemp are joint senior authors.

**Acknowledgements**

This work was carried out in the departments of Molecular Medicine, Respiratory Medicine and Critical Care at the National Heart and Lung Institute, Imperial College London, United Kingdom. The work is funded by a Medical Research Council (MRC) Clinical fellowship to Dr Bloch GD0901955/1 and was supported by the NIHR Respiratory Biomedical Research Unit (BRU) at the Royal Brompton and Harefield National Health Service (NHS) Foundation Trust and Imperial College. The NIHR Respiratory BRU at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College fund the salary of AD and part fund the salaries of MIP and MG. AL and PK are funded by Imperial College London. AL received some salary support from COPD-MAP, an MRC-funded partnership (G1001362). The funding bodies had no input into the design of the study, the collection, analysis or interpretation of data or the writing or submission of the manuscript.

**Author details**

1. Molecular Medicine, National Heart and Lung Institute, Imperial College, SW7 2AZ London, UK. 2. National Institute for Health Research (NIHR) Respiratory Biomedical Research Unit at the Royal Brompton & Harefield NHS Foundation Trust and Imperial College, SW3 6NP London, UK. 3. Leukocyte Biology, National Heart and Lung Institute, Imperial College London, London, UK.

Received: 14 July 2014 Accepted: 3 March 2015

**Published online: 07 April 2015**

**References**

1. Polkey MI, Moxham J. Clinical aspects of respiratory muscle dysfunction in the critically ill. Chest. 2001;119:363–39.
2. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011;10:631–41.
3. Tennila A, Salmi T, Pettita V, Roini RO, Varpula T, Takkunen O. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med. 2000;26:1360–3.
4. Putricheswar ZA, Raval J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310:1591–600.
5. De Jonghe B, Shanhar T, Lefaucher J, Authier F, Durand-Zaleski I, Boussarar M, et al. Paresh acquired in the intensive care unit: a prospective multicenter study. JAMA. 2002;288:2859–67.
6. Fletcher S, Kennedy D, Ghozzi I, Misra V, Kiff K, Coakley J, et al. Persistent neuromuscular and neuropsychologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med. 2003;31:1012–6.
7. Steiner MC, Roubenoff R, Tal-Singer R, P腱 et al. Regulation of muscle mass by microRNAs in human diseases. Expert Rev Mol Diagn. 2013;13:183–204.
8. Donalson AD, Ntanek SA, Lewis A, Man WD, Hopkins NS, Polkey MI, et al. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax 2013;68:1140–9.
9. Deddens JC, Colijn JM, De Hoon DJ, Hoogeveen SL, van der Velden PA, et al. Circulating miRNAs as novel biomarkers for the diagnosis of acute coronary syndrome. J Cardiovasc Transl Res 2013;6:841–48.
10. de Gruyter BV, Studer B, Tramontana G, Gruenthal A, van de Loo WJ, et al. MicroRNA-181a is an early biomarker of acute myocardial infarction. Circ Cardiovasc Genet. 2009;2:609–14.
11. Van Rooijen M, de Vries S, van Eijk K, de Vries M, van der Velden PA, et al. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges. Clin Biochem. 2013;46:846–60.
12. Donalson AD, Ntanek SA, Lewis A, Man WD, Hopkins NS, Polkey MI, et al. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax 2013;68:1140–9.
13. Lewis A, Riddoch-Contreras J, Natanek SA, Donalson A, Man WD, Moxham J, et al. Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. Thorax 2012;67:26–34.
14. Chen JF, Callis TE, Wang DZ. microRNAs and muscle disorders. J Cell Sci. 2009;12:13–20.
15. Nagubinova I, Arneyza-Zonnova M, Poleskaya A, Ali-Ali S, Groisman R, Soudi M, et al. The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat Cell Biol. 2006;8:278–84.
16. Bloch SA, Lee JY, Sybora T, Rosendahl U, Griffiths MJ, Kemp PR, et al. Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs. Thorax 2015;70(3):219–28. doi:10.1136/thoraxjnl-2014-206225.
17. Bloch SA, Lee JY, Wort SJ, Polkey MI, Kemp PR, Griffiths MJ. Sustained elevation of circulating growth and differentiation factor-15 and a dynamic imbalance in mediators of muscle homeostasis are associated with the development of acute muscle wasting following cardiac surgery. Crit Care Med. 2013;41:982–9.
18. Nashef SA, Rizques F, Michel P, Gauduchon E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9–13.
19. Seymour J, Ward K, Siddhu P, Puthucheary Z, Steier J, Jolley C, et al. Ultrasound measurement of rectus femoris cross-sectional area and the relationship with quadriceps strength in COPD. Thorax 2009;64:18–23.
20. Shinkrishna D, Patel M, Tannier RJ, Seymour JM, Connolly BA, Puthucheary ZA, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J. 2012;40(3):1115–22. doi:10.1183/09031936.00170111.
21. Koh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2013;50:298–301.
22. Stevens RD, Marshall SA, Comblath DR, Hoke A, Needham DM, de Jonghe B, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2009;37:529–38.
23. Harris ML, Luo YM, Watson AC, Rafferty GF, Polkey MI, Green M, et al. Adductor pollicus twitch tension assessed by magnetic stimulation of the ulnar nerve. Am J Respir Crit Care Med. 2000;162:240–5.
24. Wang H, Zhang P, Chen W, Feng D, Jia Y, Xie X. Evidence for serum miR-15a and miR-16 levels as biomarkers that distinguish sepsis from systemic inflammatory response syndrome in human subjects. Clin Chem Lab Med. 2012;50:1423–8.
25. Aj J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Comm. 2010;391:73–7.
26. Hutchison ER, Kawamoto EM, Taub DD, Lal A, Abdelmohsen K, Zhang Y, et al. Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. Glia 2013:61:1018–28.
27. Cadena SM, Tomkinson KN, Monnell TE, Spaitis MS, Kumar R, Underwood KW, et al. Administration of a soluble activin type IIIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol. 2010;109:535–42.
28. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142:531–43.
29. Sun X, Sit A, Feinberg MW. Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc Med. 2014;24(3):105–11. doi:10.1016/j.tcm.2013.09.002.
30. Bloch SA, Polkey MI, Griffiths MJ, Kemp P. Molecular mechanisms of intensive care unit-acquired weakness. Eur Respir J. 2012;39:1000–11.
31. Sun X, Icli B, Wata AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest. 2012;122:1973–90.